Brief: Neurocrine Biosciences Q1 Adjusted EPS USD 0.7 Vs. IBES Estimate USD 0.54
05/05/2025 21:01
May 05 (Reuters) - Neurocrine Biosciences Q1 adjusted net income USD 71.5 million vs. IBES estimate USD 63.6 million. Q1 EPS USD 0.08 Q1 product sales USD 545.2 million Q1 net income USD 7.9 million
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall